|1.||Volchegorskiĭ, I A: 18 articles (01/2014 - 01/2004)|
|2.||Rassokhina, L M: 10 articles (04/2015 - 03/2009)|
|3.||Miroshnichenko, I Iu: 7 articles (01/2014 - 03/2009)|
|4.||Kalugina, A V: 5 articles (04/2015 - 01/2014)|
|5.||Malkin, M P: 4 articles (04/2015 - 01/2014)|
|6.||Miroshnichenko, I Yu: 3 articles (04/2015 - 05/2013)|
|7.||Volchegorskii, I A: 3 articles (04/2015 - 05/2013)|
|8.||Faĭzullin, R M: 3 articles (01/2014 - 01/2014)|
|9.||Priakhina, K E: 3 articles (01/2014 - 01/2014)|
|10.||Novoselov, P N: 3 articles (09/2009 - 01/2007)|
09/01/2003 - "[Emoxipin in combined pharmacological defense of the kidney from ischemia and operative stress (an experimental study)]."
01/01/2011 - "Experiments on rats showed that 2-ethyl-6-methyl-3-hydroxypyridine hemisuccinate increases cerebral blood flow in the system of carotid arteries both in intact animals and under conditions of global transient ischemia. "
07/01/1994 - "Emoxypine in a dose of 1 nM in total ischemia was shown to have a protective action, by decreasing reperfusion contracture. "
07/01/1994 - "The efficacy of emoxypine (2-ethyl-6-methyl-3-hydroxypyridine chlorohydrate) versus sodium hydroxybutyrate in total and local ischemia followed by reperfusion was studied in the experiments on rat isolated hearts. "
01/01/2015 - "[THE INFLUENCE OF MEXIDOL AND 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE HEMISUCCINATE ON LIPOFUSCINE CONTENT IN RAT BRAIN UNDER LOCAL PERMANENT ISCHEMIA CONDITIONS]."
01/01/2004 - "A prospective placebo-controlled study was performed to examine the effects of emoxipine, reamberine, and mexidole on the severity of neuropathic and anxiety-depressive symptom clusters, by simultaneously evaluating the parameters of the lipid peroxidation-antioxidative defense protection (LPO-AOD) system in diabetic patients with the diabetic foot. "
01/01/2005 - "[Effects of emoxipine, reamberine and mexidol on neuropathic symptoms and a systolic function of the left ventricular myocardium in patients with diabetes mellitus and diabetic foot syndrome]."
01/01/2005 - "To compare efficacy of 3-oxypiridine and succinic acid derivatives (emoxipine, reamberine and mexidol) in distal neuropathy (DN) and left ventricular myocardium systolic function (LVMSF) in diabetic patients with diabetic foot syndrome (DFS). "
01/01/2005 - "An effect of 3-oxypiridine and succinic acid derivates--emoxipine, reamberin and mexidole--on severity of clinical symptoms of distal sensomotor polyneuropathy, anxiety and depression was studied in 120 patients with diabetes mellitus with syndrome of diabetic foot. "
01/01/2011 - "[Efficacy of emoxipine and mexidol in patients with chronic disorders of the digestive system and atherosclerosis of the abdominal aorta]."
01/01/2011 - "The influence of emoxipine (2-ethyl-6-methyl-3-hydroxypyridine hydrochloride) and mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate) on the content of lipid peroxidation products in peripheral blood and the dynamics of clinical symptoms of gastrointestinal tract pathology has been studied in patients of middle and senile age with atherosclerosis in the abdominal aorta. "
01/01/1991 - "Mildronate, dalargin, rokornal, emoxipine and plasmapheresis were shown to exert a beneficial effect on the regional circulation, lipid metabolism and can be used in the treatment of patients with concomitant forms of atherosclerosis."
01/01/1991 - "The loading tests, instrumental and biochemical methods were employed to study the effect of mildronate, dalargin, rokornal, gevilon, dibunol, emoxipine and plasmapheresis on the coronary, cerebral, peripheral circulation, the level of cholesterol, its fractions and triglycerides in 247 patients suffering from atherosclerosis. "
01/01/1990 - "[The efficacy of treating patients with intraocular hemorrhages with emoxypin]."
01/01/1990 - "In order to study therapeutic effectiveness of emoxipin in intraocular hemorrhages of different genesis, the preparation was used subconjunctivally, 0.5 ml of a 1% solution daily for 10-15 days. "
01/01/1991 - "[Pathogenetic bases of the use alpha-tocopherol and emoxypin in acute hemorrhage]."
01/01/1990 - "Emoxipin was used in 29 patients (29 eyes) with intraocular hemorrhages, of them, due to contusion of the eye--in 19, hypertonic disease--in 6, thrombosis of the central retinal vein--in 2, after intraocular operations--in 2 patients. "
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
05/01/2002 - "The administration of emoxypine reduced the incidence of myocardial ischemia and positively influenced the QT interval variance and the main parameters of homeostasis."
07/01/1994 - "[The comparative efficacy of emoxipine and sodium oxybutyrate in experimental myocardial ischemia]."
09/01/1990 - "The effects of synthetic antioxidant emoxypine on infarct size and plasma creatine kinase (CK) activity was studied on open-chest anesthetized dogs with 180-min myocardial ischemia followed by reperfusion. "
09/01/1997 - "[Effects of emoxipine and histochrome on lipid peroxidation and activity of serum MB-creatine phosphokinase in patients with ischemic heart disease during aortocoronary shunting]."
|2.||Succinic Acid (Succinate)
|4.||Sodium Oxybate (gamma Hydroxybutyrate)
|8.||Ophthalmic Solutions (Eye Drops)
|10.||Ascorbic Acid (Vitamin C)
|2.||Drug Therapy (Chemotherapy)